|Bid||0.21 x 900|
|Ask||0.21 x 900|
|Day's Range||0.2000 - 0.2141|
|52 Week Range||0.1920 - 1.3500|
|Beta (3Y Monthly)||-0.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.75|
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ReWalk Robotics, Ltd. (RWLK), a company that develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk recently announced a new funding program and will receive aggregate gross proceeds of approximately $12.1 million from the offering. ReWalk intends to use the net proceeds from the offering for sales, marketing and reimbursement expenses related to market development activities and broadening third-party payor coverage, research and development costs related to developing its lightweight ''soft suit'' exoskeleton technology for various lower limb disabilities, including stroke and other indications affecting the ability to walk, and the repayment of certain outstanding indebtedness.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced underwritten public offering of 12,401,390 units and 26,259,332 pre-funded units at a price to the public of $0.30 per common unit and $0.29 per pre-funded unit, which includes purchase of an additional 5,799,108 ordinary shares and common warrants to purchase an additional 5,799,108 ordinary shares purchased pursuant to the exercise in full of the underwriters’ option to purchase additional securities. Each unit contains one ordinary share (or, in the case of the pre-funded units, one pre-funded warrant) and one common warrant to purchase an ordinary share. Each common warrant has an exercise price of $0.30 per share and is exercisable immediately until five years from the date of issuance.
YOKNEAM ILIT, ISRAEL and MARLBOROUGH, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced the pricing of an underwritten public offering of 38,660,722 units at a price to the public of $0.30 per unit. Each unit contains one ordinary share (or ordinary share equivalent) and one common warrant to purchase one ordinary share. H.C. Wainwright & Co. is acting as lead book-running manager for the offering.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 15, 2018 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company") applauds United Spinal Association's recommendation, dated November 9, 2018, that health insurance providers consider the use of powered exoskeleton devices as medically necessary for eligible individuals with spinal cord injuries (SCI) in both the institutional and home settings who meet the applicable Food and Drug Administration (FDA) indications for use. According to United Spinal Association, exoskeletons have the potential to enable more than 40% of the SCI population to resume ambulation, which can lead to a healthier and improved quality of life, and the benefits of increased physical activity translate into improvements in health outcomes and decreased utilization of high healthcare costs.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 9, 2018 /PRNewswire/ -- ReWalk Robotics Ltd. (RWLK) ("ReWalk" or the "Company") announced today that the company has placed its 500th robotic exoskeleton medical device. The majority of these devices are personal systems used by individuals with spinal cord injury in their homes and communities, while others are located in rehabilitation centers to evaluate and train potential new device owners. To continue its growth, the Company is focused on expanding insurance coverage of exoskeletons for all persons with spinal cord injury and has helped develop national coverage policies with payers in several countries, including Germany, Italy and the U.S. Department of Veterans Affairs in the U.S.
ReWalk (RWLK) delivered earnings and revenue surprises of 13.33% and -23.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Yokneam Ilit, Israel-based company said it had a loss of 13 cents. The maker of wearable robotic exoskeletons that help paralyzed patients walk posted revenue of $1.6 million ...
— Total revenue of $1.6 million during the third quarter of 2018 — — Recruitment completed for the ReStore soft exo-suit clinical study — YOKNEAM ILIT, Israel and.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 05, 2018 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its.
A look at the shareholders of ReWalk Robotics Ltd (NASDAQ:RWLK) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...
BOSTON , Aug. 28, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether ReWalk Robotics ("ReWalk" ...
Rewalk Robotics shares are trading at roughly $1 a share - a far cry from the $25 threshold reached in September 2014 following its IPO on the Nasdaq.
The Yokneam Ilit, Israel-based company said it had a loss of 18 cents per share. The maker of wearable robotic exoskeletons that help paralyzed patients walk posted revenue of $1.8 million in the period. ...
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / ReWalk Robotics Ltd. (NASDAQ: RWLK ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, July 30, 2018 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company") announced today that Retired Marine Captain Derek Herrera, the first American to obtain a ReWalk Personal system after FDA clearance in 2014, has gained approval to receive a new exoskeleton system courtesy of the U.S. Department of Veterans Affairs procurement program. The VA's policy to provide exoskeletons to paralyzed Veterans was issued in 2015 and benefits Veterans with either service or non-service connected spinal cord injuries. A June 2018 revision to the policy expanded access to training locations across the VA spinal cord injury care network as well as to private rehabilitation centers through the VA's Veterans Choice Program.
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Shares of ReWalk soared over 70% on Friday after the company announced that the U.S. Department of Veterans Affairs has issued a revision to its national policy on exoskeleton medical device training and procurement for qualifying Veterans with spinal cord injury (SCI). Shares of iRobot dropped about 5%. ReWalk Robotics Ltd. shares closed up almost 74% on Friday with a little over 21 million shares traded.
The Israel-based company said that the aforementioned agency issued a revision to the company’s national policy regarding its exoskeleton medical device training and procurement for qualifying Veterans with spinal cord injury (SCI). Plus, the announcement also means that more veterans will have access to Rewalk Robotics training program locations across the VA network, as well as expanded access to private rehabilitation centers through the company’s Veterans Choice Program.